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Previewsin inflamed tissues (Helft et al., 2010).
Previous studies have shown that en-
forced PU.1 expression in monocytes
pushes them toward DC differentiation
(Bakri et al., 2005; Laiosa et al., 2006).
However, the role of endogenous PU.1
levels in monocyte-derived DC differenti-
ation in the steady state and in the inflam-
matory settings remains to be examined
in details.
Importantly, enforced Flt3 expression in
PU.1-deficient progenitors did not rescue
DC differentiation in vivo, suggesting that
PU.1 control of DC differentiation is not
limited to the regulation of Flt3 expres-
sion. PU.1 modulates the expression of
receptors for the cytokines M-CSF and
GM-CSF and interacts with the transcrip-
tions factors IRF-4, IRF-8, and CEBP-a
(Dakic et al., 2007). Modulation of these
molecules could affect DC lineage
commitment, DC differentiation, and DC
homeostasis in the periphery (Merad and
Manz, 2009). Elimination of PU.1 specifi-
cally in early myeloid precursors, DC-committed precursors, and mature DCs
should help delineate the exact role of
PU.1 at different stage of DC differentia-
tion in vivo.
Although large amounts of clinical and
experimental data support the clinical
use of DC vaccines, these data have
also showed that current DC vaccines
are not optimal for the treatment of human
disease (Steinman and Banchereau,
2007). The increasing evidence that DCs
are functionally specialized could and
should be utilized to improve DC vaccine
efficacy in patients. However, in order to
generate functionally specialized DCs de
novo, for example from MDPs, CDPs, or
monocytes, it is critical that the correct
environmental cues are present to ensure
accurate differentiation program. Thus
the ability to recreate DC developmental
programs in vitro is dependent upon our
success in defining these programs
in vivo. Understanding how DC differenti-
ation is controlled will be an essential step
toward this goal.ImmunityREFERENCES
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Is transforming growth factor-b (TGF-b) required for induction of the transcription factor Foxp3 in developing
thymocytes? Ouyang et al. (2010) demonstrate that TGF-b in the thymus prevents deletion of Foxp3+
regulatory T cells.Transforming growth factor-b (TGF-b) is
a regulatory cytokine that has pleiotropic
effects on many different cells types
(Li and Flavell, 2008). Although TGF-b
exists in three isoforms, TGF-b1 is the
predominant form expressed in the
immune system. Active TGF-b signals by
binding simultaneously to two transmem-
brane serine-threonine kinase receptors,
TGF-b receptor I (TGF-bRI) and TGF-b
receptor II (TGF-bRII). TGF-b elicits
diverse cellular responses that are pri-
marily mediated through the actions of
the Smad family of transcription factors,
but TGF-b can also signal via Smad-inde-pendent pathways. The phenotype of
TGF-b1-, TGF-bRI-, and TGF-bRII-defi-
cient animals closely resembles that of
animals deficient in the transcription
factor Foxp3 that lack regulatory T (Treg)
cells, and all mutant strains develop
a lethal autoimmune syndrome and die
at 3–4 weeks of age. Given that TGF-b
plays a critical role in the induction of
Foxp3+ T cells in vitro and in extrathymic
sites in vivo, these studies have raised
the possibility that TGF-b may play a role
in the induction of Foxp3+ T cells during
thymic development. Although this ques-
tionmight be easily addressed by analysisof Treg cell populations in TGF-b1-defi-
cient mice, these mice have relatively
normal numbers of Treg cells in the thy-
mus before inflammation develops (Marie
et al., 2005), given that they receive
maternal TGF-b protein from their
mother’s milk. A potential role for TGF-b
in the induction of the development of
Foxp3+ Treg cells in the thymus of TGF-
bRI-deficient mice has been described
(Liu et al., 2008). In this issue of Immunity,
Ouyang et al. (2010) use TGF-bRII-defi-
cient mice and present an alternative
model by demonstrating that TGF-b is
critical for the development of Foxp3+32, May 28, 2010 ª2010 Elsevier Inc. 585
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Figure 1. TGF-b Is Necessary for Inhibiting Caspase Activation and Apoptosis of Foxp3+
T Cells in the Thymus
Foxp3+ T cells in the thymus of 3- to 5-day-old TGF-b RII-deficient mice have a 10-fold higher degree of
caspase activity (not shown) than in wild-type mice. In the absence of TGF-bRII signaling, Foxp3+ T cells
have higher amounts of the proapoptotic protein Bim, a regulator of apoptosis during negative selection in
the thymus. Deletion of Bim substantially protects Foxp3+ T cells from apoptotic cell death.
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PreviewsT cells in the thymus by preventing
Bim-dependent apoptosis rather than by
inducing Foxp3 expression.
Very few CD4+Foxp3+ cells could be
detected in the thymus of the TGF-bRI-
deficient mice between 3 and 5 days of
age, whereas the number of CD4+Foxp3
T cells appeared to be normal (Liu et al.,
2008). Surprisingly, intrathymic Foxp3+
T cells expanded beginning at 7 days of
age, and at 3–4 weeks of age, the number
of Foxp3+ cell in the thymus was higher
than normal. Most importantly, thymo-
cytes from the TGF-bRI-deficient mice
had enhanced interleukin-2 (IL-2) produc-
tion and it seemed likely that IL-2 was
driving the proliferation of the few
CD4+25+Foxp3+ cells that developed in
the absence of TGF-b signaling. The role
of IL-2 in the expansion of the Foxp3+ T
cells was conclusively demonstrated by
breeding the TGF-bRI deficient mice to
IL-2-deficient mice. Whereas deletion of
IL-2 alone resulted in slightly fewer
Foxp3+ thymocytes, the doubly deficient
mice completely lacked Foxp3+ thymo-
cytes at 3–4 weeks of age. In addition,
there was a complete absence of Foxp3+
Treg cells in spleen and the mice rapidly
succumbed to autoimmune inflammation.
Although the authors concluded that
TGF-b signaling is required for the devel-
opment of Foxp3+ Treg cells in the thy-
mus, it remains unclear at what stage
and in which thymocyte population TGF-b
mediated this process.
Normal to increased numbers of
Foxp3+ T cells in the thymus of 2- to
3-week-old TGF-bRII-deficient mice were
also observed (Li et al., 2006), but earlier
time points were not examined. However,
a decrease in the percentage of Treg cells
among peripheral CD4+ T cells was
observed, and this was interpreted as
being secondary to the requirement for
TGF-b for peripheral Treg cell survival
(Marie et al., 2005). In the present study,
Ouyang et al. (2010) have re-explored in
depth the role of TGF-b in controlling the
survival of both conventional T cells and
Treg cells during thymic negative selec-
tion and development. They bred the
TGF-bRII-deficient mice to mice express-
ing the OT-II TCR transgene on a RAG-
deficient background. Blockade of TGF-b
signaling in OT-II cells resulted in their
heightened deletion in the thymus. Simi-
larly, increased apoptosis was observed
in TCR-bhi T cells from the TGF-bRII-defi-586 Immunity 32, May 28, 2010 ª2010 Elsevicient mice when thymocytes were stimu-
lated with anti-CD3 in vitro. TGF-b also
controlled peripheral T cell tolerance to
a ‘‘neo-self’’ antigen, ovalbumin. Although
wild-type OT-II mice expressing a trans-
gene encoding membrane ovalbumin did
not develop diabetes, the same mice
lacking TGF-bRII developed severe dia-
betes between 6 and 10 weeks of age.
Even though these mice demonstrated
enhanced thymic negative selection of
conventional T cells in the absence of
TGF-b signaling, an intact TGF-b signaling
pathway was also essential for the main-
tenance of tolerance in the periphery. As
was observed in the TGF-bRI-deficient
mice (Liu et al., 2008), the number of
Foxp3+ thymocytes was reduced by
80% in 3- to 5-day-old TGF-bRII-deficient
mice. Notably, Foxp3+ T cells in the TGF-
bRII mice expressed high amounts of
caspase, as well as higher numbers of
cells expressing the proliferation marker
Ki-67, and manifested a 5-fold increase
in cell death when cultured for 12 hr
in vitro. Themajor mechanistic advance in
these studies was the demonstration
that enhanced apoptosis of TGFb-RII-
deficient Treg cells was associated with
high amounts of the proapoptotic Bcl-2
family members Bim, Bak, and Bax
(Figure 1). Bim deficiency restored periph-
eral Treg cells, inhibited T cell activation,
and enhanced the lifespan of deficient
mice, but could not prevent the develop-er Inc.ment of lethal inflammation. Bim ablation
did not completely rescue caspase acti-
vation in TGF-bRII-deficient mice, raising
the possibility that other Bcl-2 family pro-
teins might control Bim-independent cas-
pase activation. The authors conclude
that TGF-b signaling is not required for
Foxp3+ Treg cell development, but rather
that the antiapoptotic effects of TGF-b are
required for Treg cell survival.
Although many studies have focused
on the negative effects of TGF-b on
immune responses, the demonstration
that TGF-b exerts positive long-term
growthpromoting effects onT cells aswell
as protection from apoptosis has been
known for almost 20 years (reviewed in
Golstein and Wyllie, 2001). For example,
TGF-b increased proliferation and IFN-g
production in CD8+ T cells, and TGF-b
and IL-2 were shown to synergize in the
prevention of apoptotic death of Th2 cell
effectors leading to prolonged expansion
of the effector populations. TGF-b has
been shown to modulate activation in-
duced T cell death by inhibiting the induc-
tion of FasL mRNA. One of the most
convincing studies of the antiapoptotic
function of TGF-b was the demonstration
of an increase in apoptosis in TGF-b-defi-
cient thymocytes that occurred before
overt signs of inflammation and immuno-
pathology developed and was evident
even in day 18 fetal thymocytes (Chen
et al., 2001). Surprisingly, exogenous
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PreviewsTGF-b failed to rescue spontaneous and
death-receptor-mediated T cell apoptosis
in TGF-b-deficient T cells, and enhance-
ment of spontaneous or TCR-induced
death was not observed in T cells defi-
cient in Smad3. One possible explanation
for these results was that TGF-b was
acting intracellularly and exerting its
antiapoptotic effects by maintaining the
integrity of mitochondrial membranes.
Although this study did not examine
apoptosis of Foxp3+ T cells in the thymus,
the results are quite compatible with all of
the observations of Ouyang et al. (2010)
and support the conclusion that the
decreased number of Foxp3+ Treg cells
early in life in the receptor-deficient mice
is secondary to enhanced apoptosis.
Collectively, these studies strongly
support the view that TGF-b is not essen-
tial for the induction of Foxp3 expression
during Treg cell development in the thy-
mus. It is clear in both studies (Liu et al.,
2008; Ouyang et al., 2010) that low
numbers of Foxp3+ thymocytes can be
detected at day 3–4 of life in the TGF-b
receptor-deficient strains. The factors
that are required for the generation of
these cells remain unknown. The studiesfrom the Li laboratory (Ouyang et al.,
2010) demonstrate that the low numbers
of Foxp3+ T cells detected at day 3–4 of
life are secondary to enhanced Bcl-2
family-mediated apoptosis, but the few
surviving cells are highly activated and
proliferating. Why then are relatively nor-
mal numbers of Foxp3+ T cell observed
at 2–4 weeks of age? It is likely that IL-2
is responsible for the expansion of the
Foxp3+ T cells to near normal numbers
on day 14 of life (Liu et al., 2008). In
many respects, the more important take-
home lesson from this series of papers
(Chen et al., 2001; Liu et al., 2008; Li and
Flavell, 2008; Ouyang et al., 2010) is
the equally critical role of TGF-b in the
development of conventional T cells by
enhancing cell survival. Furthermore, it
remains unclear how the TGF-b-mediated
survival signals control and maintain the
balance between the development of
conventional T cells and Treg cells. Lastly,
the cell type(s) responsible for the pro-
duction of TGF-b in the thymus remain
unknown. Although almost all cells can
produce TGF-b, one intriguing possibility
is that thymic Foxp3+ cells themselves
are a major source. It has recently beenImmunityshown (Tran et al., 2009) that activated
Foxp3+ T cells express latent TGF-b
bound to their surface via a leucine-rich
repeat protein termed GARP. Thus, Treg
cells functioning in a positive feedback
loop could provide the TGF-b needed for
their own survival as well as the survival
of conventional T cells.
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In this issue of Immunity, Blanchet et al. (2010) report that human immunodeficiency virus-1 inhibits macro-
autophagy in dendritic cells, attenuating MHC II presentation. Lee et al. (2010) previously revealed the
requirement of autophagic machinery for MHC II presentation of herpes viral antigens.For many years, macroautophagy was
relegated to a role of indiscriminate bulk
degradation during periods of nutrient
stress in eukaryotes. More recent studies,
however, have secured evidence for an
increasing variety of roles for autophagy
during innate and adaptive immune sur-
veillance and pathogen degradation. It
is becoming clear that autophagy has
evolved beyond its origins of ‘‘self-eating’’into well-adapted self-defense (Levine
and Deretic, 2007).
Numerous in vitro studies have shown
that autophagic engulfment of free intra-
cellular bacterial and viral pathogens can
eliminate these pathogens from host
cells. Some pathogens, including Shigella
flexneri and Legionella pneumophila, and
herpes viruses HSV-1 and KSHV, are
able to evade autophagosomal degrada-tion and in some cases even subvert auto-
phagosomes and autolysosomes for their
own proliferation (Levine and Deretic,
2007; Schmid and Munz, 2007). Autoph-
agy also promotes the activation of
proinflammatory responses during innate
immunity, primarily through engulfment
and delivery of pathogen-associated
molecular patterns (PAMPs) to pattern
recognition receptors (PRRs) including32, May 28, 2010 ª2010 Elsevier Inc. 587
